Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
21. Februar 2024 08:30 ET
|
Coherus BioSciences, Inc.
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
05. Februar 2024 08:00 ET
|
Coherus BioSciences, Inc.
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be...
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
22. Januar 2024 01:15 ET
|
Coherus BioSciences, Inc.
– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus...
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
18. Januar 2024 16:05 ET
|
Coherus BioSciences, Inc.
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel...
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03. Januar 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P....
Coherus Announces U.S. Launch of LOQTORZI™
02. Januar 2024 08:29 ET
|
Coherus BioSciences, Inc.
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients...
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
26. Dezember 2023 16:01 ET
|
Coherus BioSciences, Inc.
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...
Coherus BioSciences Announces New Employment Inducement Grants
22. Dezember 2023 17:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation...
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
11. Dezember 2023 08:30 ET
|
Coherus BioSciences, Inc.
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with...
Coherus BioSciences Announces CFO Transition Plans
07. Dezember 2023 17:55 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the...